Login / Signup

Galactose-Deficient IgA1 as a Candidate Urinary Marker of IgA Nephropathy.

Yusuke FukaoHitoshi SuzukiJin Sug KimKyung Hwan JeongYuko MakitaToshiki KanoYoshihito NiheiMaiko NakayamaMingfeng LeeRina KatoJer-Ming ChangSang Ho LeeYusuke Suzuki
Published in: Journal of clinical medicine (2022)
In patients with IgA nephropathy (IgAN), circulatory IgA1 and IgA1 in the mesangial deposits contain galactose-deficient IgA1 (Gd-IgA1). Some of the Gd-IgA1 from the glomerular deposits is excreted in the urine and thus urinary Gd-IgA1 may represent a disease-specific marker. We recruited 338 Japanese biopsy-proven IgAN patients and 120 patients with other renal diseases (disease controls). Urine samples collected at the time of renal biopsy were used to measure Gd-IgA1 levels using a specific monoclonal antibody (KM55 mAb). Urinary Gd-IgA1 levels were significantly higher in patients with IgAN than in disease controls. Moreover, urinary Gd-IgA1 was significantly correlated with the severity of the histopathological parameters in IgAN patients. Next, we validated the use of urinary Gd-IgA1 levels in the other Asian cohorts. In the Korean cohort, urinary Gd-IgA1 levels were also higher in patients with IgAN than in disease controls. Even in Japanese patients with IgAN and trace proteinuria (less than 0.3 g/gCr), urinary Gd-IgA1 was detected. Thus, urinary Gd-IgA1 may be an early disease-specific biomarker useful for determining the disease activity of IgAN.
Keyphrases
  • end stage renal disease
  • disease activity
  • chronic kidney disease
  • newly diagnosed
  • systemic lupus erythematosus
  • ejection fraction
  • peritoneal dialysis
  • patient reported outcomes
  • high glucose